Cargando…
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo
Current understanding suggests that malignant stem and progenitor cells must be reduced or eliminated for prolonged remissions in myeloid neoplasms such as acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Multicolor flow cytometry has been widely used to distinguish stem and myelo...
Autores principales: | Knorr, Katherine L.B., Finn, Laura E., Smith, B. Douglas, Hess, Allan D., Foran, James M., Karp, Judith E., Kaufmann, Scott H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442784/ https://www.ncbi.nlm.nih.gov/pubmed/28297583 http://dx.doi.org/10.5966/sctm.2016-0034 |
Ejemplares similares
-
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008) -
Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Umbilical Cord Blood
por: Sotnezova, E.V., et al.
Publicado: (2016) -
Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020) -
Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
por: Molina, Manuel, et al.
Publicado: (2015) -
Characteristics of Clostridium difficile infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia
por: Shah, Kamini, et al.
Publicado: (2017)